Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CheckMate 816: Nivolumab-Based Neoadjuvant Therapy in Early Stage NSCLC
2022-501360-18-00Phase 3Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Apr 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 14
01
Overview
Phase 3, randomised, open-label trial of nivolumab and ipilimumab in non-small cell lung cancer (NSCLC) (3 arms), sponsored by Bristol Myers Squibb. Primary endpoints: Event-Free Survival and Pathological Complete Response. Started Apr 2023; status: completed.
02
Drugs
nivolumabipilimumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2022-501360-18-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-501360-18-00.